BioCorRx Statistics
Total Valuation
BioCorRx has a market cap or net worth of $12.96 million. The enterprise value is $18.53 million.
| Market Cap | 12.96M |
| Enterprise Value | 18.53M |
Important Dates
The last earnings date was Wednesday, March 29, 2023.
| Earnings Date | Mar 29, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
BioCorRx has 17.28 million shares outstanding. The number of shares has increased by 12.40% in one year.
| Shares Outstanding | 17.28M |
| Shares Change (YoY) | +12.40% |
| Shares Change (QoQ) | +1.04% |
| Owned by Insiders (%) | 61.88% |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 145.34 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 207.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.03
| Current Ratio | 0.03 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.89 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -968.64% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $29,720 |
| Profits Per Employee | -$1.26M |
| Employee Count | 3 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3,578 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.93% in the last 52 weeks. The beta is 0.85, so BioCorRx's price volatility has been lower than the market average.
| Beta (1Y) | 0.85 |
| 52-Week Price Change | -61.93% |
| 50-Day Moving Average | 1.02 |
| 200-Day Moving Average | 1.33 |
| Relative Strength Index (RSI) | 35.32 |
| Average Volume (30 Days) | 1,012 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioCorRx had revenue of $89,160 and -$3.77 million in losses. Loss per share was -$0.45.
| Revenue | 89,160 |
| Gross Profit | -33,717 |
| Operating Income | -3.50M |
| Pretax Income | -3.77M |
| Net Income | -3.77M |
| EBITDA | -2.75M |
| EBIT | -2.95M |
| Loss Per Share | -$0.45 |
Balance Sheet
The company has $65,222 in cash and $5.63 million in debt, giving a net cash position of -$5.57 million or -$0.32 per share.
| Cash & Cash Equivalents | 65,222 |
| Total Debt | 5.63M |
| Net Cash | -5.57M |
| Net Cash Per Share | -$0.32 |
| Equity / Book Value | -9.82M |
| Book Value Per Share | -0.57 |
| Working Capital | -6.24M |
Cash Flow
| Operating Cash Flow | -1.85M |
| Capital Expenditures | n/a |
| Free Cash Flow | -1.85M |
| FCF Per Share | -$0.21 |
Margins
Gross margin is -37.82%, with operating and profit margins of -3,924.03% and -4,224.89%.
| Gross Margin | -37.82% |
| Operating Margin | -3,924.03% |
| Pretax Margin | -4,228.90% |
| Profit Margin | -4,224.89% |
| EBITDA Margin | -3,084.05% |
| EBIT Margin | -3,308.29% |
| FCF Margin | -2,078.60% |
Dividends & Yields
BioCorRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.40% |
| Shareholder Yield | -12.40% |
| Earnings Yield | -29.07% |
| FCF Yield | -14.30% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 22, 2019. It was a reverse split with a ratio of 1:100.
| Last Split Date | Jan 22, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
BioCorRx has an Altman Z-Score of -324.49 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -324.49 |
| Piotroski F-Score | 1 |